Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Trial Profile

Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Clarithromycin (Primary) ; Docetaxel (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top